share_log

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

火箭制药公司宣布RP-L301治疗丙酮酸激酶缺乏症第一阶段试验的最新阳性初步临床数据
Benzinga Real-time News ·  2021/03/22 19:03

— Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated —

-最新数据显示，第一名患者的血红蛋白在6个月后持续改善至正常范围，第二名接受治疗的患者的血红蛋白在3个月内也有类似的改善-

— Maintained Safety and Tolerability of RP-L301 up to 6-months Post-treatment —

-维护 RP-L301在治疗后6个月内的安全性和耐受性

— Long-Term Data on Track for 2H2021 —

-2021年下半年的长期数据已步入正轨-

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发